Nasdaq: GTBP

GT Biopharma, Inc.

Shareholder letter...

GT BIOPHARMA ISSUES OPEN LETTER TO SHAREHOLDERS DETAILING RECENT ACTIVITIES

Immunotherapy for the Treatment of Cancer

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors.

View Product Pipeline

About

GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.

About

Latest News

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Nov 6, 2023 • 9:30 EST | Read More

GT Biopharma Reports Third Quarter 2023 Financial Results
Nov 1, 2023 • 9:00 EDT | Read More

Investors

GT Biopharma, Inc. Nasdaq: GTBP
Loading... Change
Loading... Volume
Loading... 52 Week Range
Investor Relations Icon
View Our Investor Relations
Click here to sign up for GT Biopharma, Inc. email alerts Email Signup Icon Be first to receive news, events and updates